Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage.

Stepanova M, Younossi ZM.

Dig Dis Sci. 2015 May 19. [Epub ahead of print]

PMID:
25986525
2.

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.

Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, Hunt SL, Marcellin P.

J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192-0. doi: 10.1016/j.jhep.2015.03.014. [Epub ahead of print]

PMID:
25795586
3.

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.

Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R.

Hepatology. 2015 May;61(5):1471-8. doi: 10.1002/hep.27757. Epub 2015 Mar 23.

PMID:
25706754
4.

Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.

Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, Kumari R, Daugherty TJ, Higgins JP, Younossi ZM, Kim WR, Glenn JS, Ahmed A.

Transpl Infect Dis. 2015 Apr;17(2):275-8. doi: 10.1111/tid.12348. Epub 2015 Jan 31.

PMID:
25641426
5.

Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.

Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL.

Hepatology. 2015 Jan 27. doi: 10.1002/hep.27724. [Epub ahead of print]

PMID:
25627448
6.

Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.

Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC.

Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.

PMID:
25619871
7.

Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease.

Elsheikh E, Younoszai Z, Otgonsuren M, Hunt S, Raybuck B, Younossi ZM.

J Gastroenterol Hepatol. 2014;29(7):1528-34. No abstract available.

PMID:
25587619
8.

Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.

Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL.

J Infect Dis. 2015 Jan 12. pii: jiv005. [Epub ahead of print]

PMID:
25583164
9.

The outcomes of adult liver transplants in the United States from 1987 to 2013.

Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM.

Liver Int. 2015 Jan 5. doi: 10.1111/liv.12779. [Epub ahead of print]

PMID:
25559873
10.

Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects.

Mehta R, Neupane A, Wang L, Goodman Z, Baranova A, Younossi ZM.

BMC Gastroenterol. 2014 Dec 16;14:208. doi: 10.1186/s12876-014-0208-8.

11.

Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease.

Karrar A, Stepanova M, Alaparthi L, Lingam S, Younoszai Z, Zheng L, Malik KS, Younossi E, Monge F, Hunt SL, Goodman Z, Younossi ZM.

J Gastroenterol Hepatol. 2015 May;30(5):900-8. doi: 10.1111/jgh.12856.

PMID:
25469790
12.

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A.

Gastroenterology. 2015 Mar;148(3):547-55. doi: 10.1053/j.gastro.2014.11.039. Epub 2014 Nov 25.

PMID:
25461851
13.

Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.

Saab S, Younossi ZM.

Aliment Pharmacol Ther. 2014 Oct;40(8):984-5. doi: 10.1111/apt.12939. No abstract available.

PMID:
25229814
14.

Survey of health status, nutrition and geography of food selection of chronic liver disease patients.

Leslie T, Pawloski L, Kallman-Price J, Escheik C, Hossain N, Fang Y, Gerber LH, Younossi ZM.

Ann Hepatol. 2014 Sep-Oct;13(5):533-40.

PMID:
25152986
15.

Resource utilization and survival among Medicare patients with advanced liver disease.

Otgonsuren M, Henry L, Hunt S, Venkatesan C, Mishra A, Younossi ZM.

Dig Dis Sci. 2015 Feb;60(2):320-32. doi: 10.1007/s10620-014-3318-9. Epub 2014 Aug 10.

PMID:
25108520
16.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.

Lancet. 2014 Nov 15;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9. Epub 2014 Jul 28. Erratum in: Lancet. 2014 Nov 15;384(9956):1748.

PMID:
25078309
17.

The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US.

Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S.

Aliment Pharmacol Ther. 2014 Sep;40(6):686-94. doi: 10.1111/apt.12881. Epub 2014 Jul 16.

PMID:
25040315
18.

Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.

Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM.

Aliment Pharmacol Ther. 2014 Sep;40(6):676-85. doi: 10.1111/apt.12880. Epub 2014 Jul 15.

PMID:
25040192
19.

A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM.

J Gastroenterol Hepatol. 2014 Dec;29(12):2006-13. doi: 10.1111/jgh.12665.

PMID:
25039333
20.

The portrait of an adult liver transplant recipient in the United States from 1987 to 2013.

Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM.

JAMA Intern Med. 2014 Aug;174(8):1407-9. doi: 10.1001/jamainternmed.2014.2903. No abstract available.

PMID:
24978860
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk